Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Scott E. Kamholz M.D., Ph.D.

Of Counsel

Scott Kamholz has scored major wins for clients in PTAB cases involving blockbuster life science technologies. He combines his experience as an Administrative Patent Judge and background in medicine, biophysics, and engineering to advise clients in the life sciences sector on a variety of complex patent litigation matters and PTAB proceedings. He has handled dozens of PTAB proceedings since returning to private practice.


  • Lead Counsel in 19 AIA proceedings since 2018.
  • Lead Counsel for patent owner in multiple IPR proceedings on patents concerning medical devices used in radiation therapy.
  • Lead Counsel for patent owner in multiple IPR procedings on patents concerning solar cells.
  • Lead Counsel for patent owner in multiple IPR proceedings on patents concerning hybrid car technology.
  • Lead Counsel for patent owner in a PGR proceeding on a patent concerning co-administration of an immune checkpoint inhibitor and a bacterial formulation including bifidobacteria.
  • Counsel for biopharma company as patent owner in an IPR challenging a patent concerning immunoglobulin production.
  • Lead Counsel for petitioner in an IPR proceeding on a patent concerning wireless communication technology.
  • Represented biopharma company as patent owner in an IPR challenging a patent concerning AVASTIN® cancer therapy. The PTAB denied institution in August 2018.
  • Advised Eli Lilly and Company as petitioner in an IPR filed against a patent owned by the Trustees of the University of Pennsylvania allegedly covering Lilly’s ERBITUX® cancer therapy. The PTAB found all challenged claims unpatentable, a decision summarily affirmed by the Federal Circuit on appeal in September 2018.
  • Advised Bristol-Myers Squibb Company as patent owner in an IPR brought by Momenta Pharmaceuticals, Inc., challenging a patent concerning ORENCIA® rheumatoid arthritis therapy. The PTAB rejected petitioner’s challenge and confirmed the patentability of all challenged claims. The Federal Circuit dismissed Momenta’s appeal for lack of standing and mootness in February 2019.
  • Represented AstraZeneca as patent owner in an IPR challenging a patent concerning SYMBICORT® asthma and COPD therapy. The PTAB denied institution in July 2017
  • Counsel of Record for Pharmaceutical Research and Manufacturers of America (PhRMA) in numerous amicus briefs before the Supreme Court of the United States and the Court of Appeals for the Federal Circuit.

Previous Experience

  • U. S. Patent Trial and Appeal Board (PTAB), Administrative Patent Judge